Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Sermorelin GHRP-2 Acetate for Research: Quality Comparison

Before selecting a peptide supplier, compare synthesis method, purity verification, and storage handling. These factors determine whether your research yields reproducible data or inconsistent results requiring protocol redesign. Solid-phase peptide synthesis

This comparison does not assign a generated winner or score.

  • Before selecting a peptide supplier, compare synthesis method, purity verification, and storage handling. These factors determine whether your research yields reproducible data or inconsistent results requiring protocol redesign.
  • Solid-phase peptide synthesis (SPPS) with HPLC purification. Industry standard for research-grade peptides
  • Third-party mass spectrometry confirming >98% purity, with COA (certificate of analysis) included per batch
  • Cold-chain shipping with temperature data loggers; lyophilised storage at −20°C before reconstitution
  • Full amino acid sequencing via Edman degradation or tandem MS to verify exact 29-AA sermorelin + 6-AA GHRP-2 structure
  • Meets research reproducibility standards. Each batch traceable and verified
  • Liquid-phase synthesis or recombinant expression. Lower cost but higher impurity risk
  • In-house HPLC only, no independent COA
  • Standard shipping without temperature monitoring; refrigerated storage claims without verification
  • Sequence confirmation by supplier statement only, no third-party validation
  • Adequate for preliminary work but insufficient for publication-quality studies
  • Undisclosed synthesis method or "proprietary process"
  • No purity documentation provided
  • No cold-chain protocol; peptides shipped at ambient temperature
  • No sequence verification available
  • Unacceptable for any research requiring reproducibility or regulatory compliance
  • Our experience working with research institutions shows the same pattern: peptide batches without third-party COAs produce GH release variance exceeding 40% between replicates, making dose-response curves unreliable. Verified >98% purity narrows that variance to under 8%, which is the threshold for publishable endocrine research.
More references

Related material